White House Urges Congress To Delay November Hemp Recriminalization
Biden administration calls for legislative fix to prevent broad hemp product ban set to take effect in five months.

A stunning daytime view of the United States Capitol in Washington DC with a clear blue sky.
Administration Signals Regulatory Concern Over Broad Statutory Language
The White House statement stops short of endorsing a specific legislative fix but warns that the current statutory language could sweep in products Congress didn't intend to ban. The November deadline stems from a provision in the 2025 appropriations bill that narrows the 2018 Farm Act's definition of hemp, effectively recriminalizing products containing delta-8 THC, delta-10 THC, and other semi-synthetic cannabinoids derived from hemp-sourced CBD.
On a strict reading of the text, the law applies to any tetrahydrocannabinol isomer not naturally occurring in the cannabis plant at concentrations above 0.3 percent by dry weight. That statutory construction would cover delta-8 vapes, gummies, and tinctures sold in gas stations and smoke shops nationwide. The Hemp Roundtable pegs the market at $28 billion annually.
The administration's statement doesn't cite a specific statute or proposed amendment. Two draft bills are circulating, congressional staffers told Marijuana Moment: one that would grandfather existing hemp products under a pre-2025 regulatory framework, and another that would direct the FDA to establish a formal rulemaking process for intoxicating hemp derivatives within 180 days.
Industry Groups Frame Deadline As Existential Threat
Hemp trade associations are warning that the November cutoff could trigger mass layoffs and a wave of business closures across 47 states that currently permit hemp-derived intoxicants under state law. The U.S. Hemp Roundtable submitted a letter to the House Agriculture Committee on June 20 estimating that 12,000 small retailers and 340 manufacturers would face immediate inventory write-offs if the ban takes effect as written.
The administration's call for "fair treatment" is a tacit acknowledgment that the 2025 language was drafted without input from USDA or FDA, both of which have regulatory jurisdiction over hemp under the Farm Act.
The trade group's letter doesn't quantify the dollar value of unsold inventory. But it notes that distributors typically carry 90 to 120 days of stock, which at current wholesale pricing implies $7 billion to $9 billion in stranded product if no legislative fix passes before the October manufacturing cutoff.
State-level hemp regulators are split. North Carolina's Department of Agriculture has publicly supported a federal delay, while Oregon's Liquor and Cannabis Commission has urged Congress to let the ban proceed and allow states to establish their own intoxicating-hemp frameworks. The split reflects a broader tension: should delta-8 and similar products be regulated as food additives (FDA), agricultural commodities (USDA), or controlled substances (DEA)?
Congressional Calendar Leaves Narrow Window For Action
Congress is scheduled to recess from July 4 through September 8. Any legislative fix must pass both chambers by late September to allow manufacturers time to adjust production before November. House Agriculture Committee Chair Glenn Thompson hasn't committed to scheduling a markup, and Senate Majority Leader Chuck Schumer hasn't indicated whether a hemp amendment could be attached to the September continuing resolution.
The White House statement doesn't threaten a veto of appropriations bills that retain the November deadline, but it signals that the administration views the current language as administratively unworkable. For full background on the evolving regulatory treatment of hemp-derived intoxicants, see the CannIntel topic hub on the federal hemp loophole.
If Congress doesn't act, enforcement responsibility will fall to the DEA and FDA. Neither agency has issued guidance on how it intends to distinguish lawful hemp extracts from newly controlled substances, and both have historically declined to prioritize enforcement of low-THC products absent a clear threat to public health. That enforcement gap is precisely what the 2025 appropriations language was designed to close, but the White House now appears to view the closure as too broad.
The next signal: whether Thompson schedules a committee vote before the July 4 recess. Without that, the odds of a legislative fix drop sharply.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Frequently asked questions
What hemp products would be banned under the November 1 deadline?
The law targets semi-synthetic cannabinoids derived from hemp, including delta-8 THC, delta-10 THC, and other THC isomers not naturally occurring in cannabis above 0.3 percent by dry weight. Products sold as gummies, vapes, and tinctures in gas stations and smoke shops would be recriminalized unless Congress amends the statute.
Why is the White House opposing a ban it previously signed into law?
The administration's statement suggests the 2025 appropriations language was broader than intended and could sweep in products Congress didn't mean to prohibit. The White House isn't calling for full repeal but urges a legislative fix to ensure "fair treatment" and avoid market disruption.
What happens if Congress does not act before November?
Manufacturers would need to halt production by early October to avoid inventory losses. Retailers holding banned products after November 1 could face DEA enforcement, though neither DEA nor FDA has issued guidance on enforcement priorities. Industry groups estimate $7 billion to $9 billion in stranded inventory.
Which states currently allow delta-8 and similar hemp products?
Forty-seven states permit hemp-derived intoxicants under state law, though regulatory frameworks vary. Oregon, Colorado, and Alaska have enacted stricter controls, while states like North Carolina and Texas allow broad retail sales under the 2018 Farm Act's hemp definition.
What are the two draft bills being considered in Congress?
One bill would grandfather existing hemp products under the pre-2025 regulatory framework, allowing continued sales while agencies develop new rules. The other would direct FDA to establish a formal rulemaking process for intoxicating hemp derivatives within 180 days, creating a legal pathway for market participants.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

New York increases social equity cannabis funding to $35 million
State expands capital pool for Conditional Adult-Use Retail Dispensary licensees by $10 million.

Asheville's Realbudz Dispensary Operates in Legal Gray Zone as NC Debate Stalls
The storefront sells cannabis products openly while state lawmakers remain deadlocked on legalization.

Connecticut finalizes tribal cannabis compact to expand market access
The state formalized an agreement allowing tribal nations to enter the cannabis industry, opening new retail and cultivation opportunities.
More from the newsroom

Missouri Opens Third Microbusiness License Round July 13
DHSS will accept 77 applications over two weeks for cultivation-only licenses reserved for social-equity applicants.

Cannabis Industry Employment Fell 2.7% in 2025, Vangst Report Finds
Job losses tracked a 3.3% decline in U.S. cannabis sales and widespread price compression across state markets.

Althea Faces TGA Regulatory Tightening as Australia Revises Rules
ASX-listed Althea confronts stricter compliance as Australia's TGA revises medical cannabis framework.